Her Health

GLP-1 drugs — bone/gout/osteo risks + regain + menopause weight

GLP-1 drugs — bone/gout/osteo risks + regain + menopause weight

Key Questions

What bone health risks come with GLP-1 drugs?

GLP-1 drugs can accelerate hip bone loss, especially in women without diabetes, due to rapid weight loss; a 30% increased osteoporosis or muscle risk occurs without adequate protein, resistance training, or creatine.

How effective is combining HRT with tirzepatide for weight loss?

A Mayo Clinic study found that HRT boosts tirzepatide weight loss by 35%, helping address menopause-related challenges like increased belly fat and cardiovascular risk.

Do GLP-1 drugs affect fracture or cancer risk?

Semaglutide is linked to a 15% lower fracture risk in type 2 diabetes, while GLP-1s overall are associated with a 41% lower risk of obesity-related cancers.

30% osteo/musc risk w/o prot/RT/creat; 70% regain; focus protein 1.2-1.5g/kg + fiber; menopause IMAT/CV/belly weight challenges. Mayo Clinic study shows HRT boosts tirzepatide weight loss by 35%. Semaglutide linked to 15% lower fracture risk in type 2 diabetes; GLP-1s linked to 41% lower obesity-related cancer risk. Accepted perspective on using deoxypyridinoline urine test to monitor bone loss during GLP-1 therapy. International Journal of Obesity treat-to-target approach reframes obesity pharmacotherapy. New this run: JCEM study shows GLP-1 drugs accelerate hip bone loss, especially in women without diabetes, driven by rapid weight loss—reinforces need for DXA, resistance training, protein, calcium.

Sources (1)
Updated Jul 24, 2026
What bone health risks come with GLP-1 drugs? - Her Health | NBot | nbot.ai